326
Views
69
CrossRef citations to date
0
Altmetric
Research Article

The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats

, , , , , , & show all
Pages 281-290 | Received 19 Oct 2005, Accepted 27 Mar 2006, Published online: 08 Oct 2008

References

  • Almeida AJ, Alpar HO, Brown MRW. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(l-lactic acid) microspheres in rats, rabbits and Guineapigs. J Pharm Pharmacol 1993; 45: 198–203
  • de Ascentiis A, de Grazia JL, Bowman CN, Colombo P, Peppas NA. Mucoadhesion of poly(2-hydroxyethyl methacrylate) is improved when linear poly(ethylene oxide) chains are added to the polymer network. J Control Release 1995; 33: 197–201
  • Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagon-like peptide-1 antagonist exendin (9–39) after intranasal administration. J Pharmacol Exp Ther 2004; 309: 469–475
  • Blardi P, Urso R, De Lalla A, Volpi L, Perri TD, Auteri A. Nimodipine: Drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin Pharmacol Ther 2002; 72: 556–561
  • Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: A transnasal approach to the human brain. Nature Neurosci 2002; 5: 514–516
  • Brooking J, Davis SS, Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Target 2001; 9: 267–279
  • Chou KJ, Donovan MD. The distribution of local anaesthetics into the CSF following intranasal administration. Int J Pharm 1998; 168: 137–145
  • Chow HHS, Chen Z, Matsuura GT. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci 1999; 88: 754–758
  • Dahlin M, Björk E. Nasal absorption of (S)-UH-301 and its transport into the cerebrospinal fluid of rats. Int J Pharm 2000; 195: 197–205
  • Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997; 14: 1568–1573
  • Dufes C, Olivier JC, Gaillard F, Gaillard A, Couet W, Muller JM. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 2003; 255: 87–97
  • Erdlenbruch B, Alipour M, Fricker G, Miller DS, Kugler W, Eibl H, Lakomek M. Alkylglycerol opening of the blood–brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol 2003; 140: 1201–1210
  • Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso M. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 1999; 16: 1576–1581
  • Frey WH, II, Liu J, Chen X, Thorne RG, Fawcett RG, Ala TA, Rahman YE. Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv 1997; 4: 87–92
  • Frey WH, II. Intranasal delivery: Bypassing the blood–brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv Technol 2002; 2: 46–49
  • Gizurarson S, Thorvaldsson T, Sigurdsson P, Gunnarsson E. Selective delivery of insulin into the brain: Intraolfactory absorption. Int J Pharm 1996; 140: 77–83
  • Graff CL, Pollack GM. Nasal drug administration: Potential for targeted central nervous system delivery. J Pharm Sci 2005; 94: 1187–1195
  • Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000; 11: 1–18
  • Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003; 87: 187–198
  • Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev 2001; 47: 83–97
  • Jani PU, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989; 41: 809–812
  • Johnson MD, Chen J, Anderson BD. Investigation of the mechanism of enhancement of central nervous system delivery of 2′-beta-fluoro-2′,3′-dideoxyinosine via a blood–brain barrier adenosine deaminase-activated prodrug. Drug Metab Dispos 2002; 30: 191–198
  • Lindhardt K, Ravn C, Gizurarson S, Bechgaard E. Intranasal absorption of buprenorphine-in vivo bioavailability study in sheep. Int J Pharm 2000; 205: 159–163
  • Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 2005; 107: 428–448
  • Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: Fact or fiction?. J Drug Target 1998; 5: 415–441
  • Muck W, Bode H. Bioanalytics of nimodipine—an overview of methods. Pharmazie 1994; 49: 130–139
  • Muck W, Breuel HP, Kuhlmann J. The influence of age on the pharmacokinetics of nimodipine. Int J Clin Pharmacol 1996; 34: 293–298
  • Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, Wallin T. Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the scandinavian multi-infarct dementia trial. J Neurol Sci 2000; 175: 124–134
  • Pardridge WM. CNS drug design based on principles of blood–brain barrier transport. J Neurochem 1998; 70: 1781–1792
  • Peppas NA. Molecular calculations of poly(ethylene glycol) transport across a swollen poly(agrylic acid)/mucin interface. J Biomater Sci Polymer Edn 1998; 9: 535–542
  • Plard JP, Bazile D. Comparison of the safety profiles of PLA50 and Me*PEG-PLA50 nanoparticles after single dose intravenous administration to rat. Colloids Surf B Biointerf 1999; 16: 173–183
  • Rameis H. Principles of the pharmacokinetics and pharmacodynamics of calcium anatagonists. Wien Med Wochenschr 1993; 143: 490–500
  • Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH, II. Intrranasal administration of interferon beta bypasses the blood–brain barrier to target the central nervous system and cervical lymph nodes: A non-invasive treatment strategy for multiple sclerosis. J Neurochem 2004; 151: 66–77
  • Tobío M, Gref R, Sánchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 1998; 15: 270–275
  • Vila A, Sánchez A, Pérez C, Alonso MJ. PLA-PEG nanospheres: New carriers for transmucosal delivery of proteins and plasmid DNA. Polym Adv Technol 2002a; 13: 1–8
  • Vila A, Sánchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release 2002b; 78: 15–24
  • Vila A, Gill H, McCallion O, Alonso MJ. Transport of PLA-PEG particles across the nasal mucosa: Effect of particle size and PEG coating density. J Control Release 2004; 98: 231–244
  • Vila A, Sánchez A, Évora C, Soriano I, McCallion O, Alonso MJ. PLA-PEG particles as nasal protein carriers: The influence of the particle size. Int J Pharm 2005; 292: 43–52
  • Wang F, Jiang X, Lu W. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm 2003; 263: 1–7
  • Westin U, Piras E, Jansson B, Bergström U, Dahlin M, Brittebo E, Björk E. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 2005; 24: 565–573
  • Yuan J. Estimation of variance for AUC in animal studies. J Pharm Sci 1993; 82: 761–763
  • Zhang JT. Altered calcium homeostasis in brain aging and senile dementia, new approach to treat Alzheimer's disease. Acta Pharm Sin 1993; 28: 641–646
  • Zhang QZ, Jiang XG, Wu CH. Distribution of nimodipine into brain following intranasal administration in rats. Acta Pharmacol Sin 2004a; 25: 522–527
  • Zhang QZ, Jiang XG, Jiang WM, Lu W, Su LN, Shi ZQ. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 2004b; 275: 85–96
  • Zhang QZ, Jiang XG, Shi ZQ, Gao KP. The effects of nimodipine on cerebral hemodynamics following intranasal administration in dogs. Acta Pharm Sin 2005; 40: 466–469
  • Zhang Y, Zhang QZ, Zha LS, Yang WL, Wang CC, Jiang XG, Fu SK. Preparation, characterization and application of pyrene-labelled methoxy poly(ethylene glycol)-poly(lactic acid) copolymer nanoparticles. Colloid Polymer Sci 2004; 282: 1323–1328

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.